See the workflow before you discuss the engagement.
The public pharma demo is a synthetic product-direction experience. It shows source organization, CTD structure, drafting, and review states; it does not prove a production deployment, client result, validation, security, privacy, or compliance.
What to inspect.
- Source structureHow preloaded synthetic material is organized before drafting.
- Dossier navigationHow CTD sections, status, and source context can remain visible.
- Review statesWhere exceptions, edits, named review, and final decisions would belong.
- Production boundaryWhich architecture, data, validation, integration, and operating questions remain to be scoped.
Four fields. Then the demo opens.
Tell us who is inspecting the workflow and what you need to see. Do not include product, patient, safety, credential, or controlled information.
Demo direction is not a universal production inclusion.
Open-source components, on-premises or hybrid deployment, orchestration, SSO, audit history, and named system integrations require engagement-specific design, authorization, testing, and operating ownership.
Assess licensing, hardware, updates, access, support, data flow, and acceptance evidence.
Assess authorized APIs, identity, mapping, failures, audit requirements, and client acceptance.
Intended use, complete-system evidence, procedures, qualified roles, and client approval determine fitness.
After the demo, bring the workflow—not the files.
A fit call with Saad starts with the bottleneck, source types, decision owner, timing, and deployment constraints at a non-confidential level.